Negative free cash flow offset by $6.9M defense funding and INL partnership; final permit clearance triggers construction catalyst for imminent price surge.
Strong gross margin and analyst buy consensus clash with negative free cash flow; no direct news catalyst, but biotech sentiment may lift RYTM in short term.